Primary tumor resection in stage IV unresectable colorectal cancer: what has changed?

被引:0
作者
Michał Pędziwiatr
Magdalena Mizera
Jan Witowski
Piotr Major
Grzegorz Torbicz
Natalia Gajewska
Andrzej Budzyński
机构
[1] Jagiellonian University Medical College,2nd Department of General Surgery
[2] Centre for Research,undefined
[3] Training and Innovation and Surgery (CERTAIN Surgery),undefined
来源
Medical Oncology | 2017年 / 34卷
关键词
Stage IV colorectal cancer; Unresectable colorectal cancer; Primary tumor resection; Decision making;
D O I
暂无
中图分类号
学科分类号
摘要
Most current guidelines do not recommend primary tumor resection in stage IV unresectable colorectal cancer. Rapid chemotherapy development over the last decade has substantially changed the decision making. However, results of recently published trials and meta-analyses suggest that primary tumor resection may in fact be beneficial, principally in terms of prolonged survival. Additional factors, such as use of minimally invasive approach or protocols of enhanced recovery after surgery, affect clinical outcomes as well, but are often neglected when discussing the state of the art in this area. There are still no randomized studies determining the legitimacy of upfront surgery in asymptomatic patients. Also, quality of life also plays an important role in choosing appropriate treatment. Having said that, there is no data that would prove whether primary tumor resection has an advantage on that issue. With all the uncertainty, currently decision making in unresectable stage IV colorectal cancer is primarily up to clinicians’ knowledge, common sense and patients’ preferences.
引用
收藏
相关论文
共 276 条
[1]  
Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386
[2]  
Soerjomataram II(2017)Global patterns and trends in colorectal cancer incidence and mortality Gut 66 683-691
[3]  
Dikshit R(2015)Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM intergroup 40004 (CLOCC) J Clin Oncol Am Soc Clin Oncol 33 3501-2626
[4]  
Eser S(2012)Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) Ann Oncol Off J Eur Soc Med Oncol 23 2619-13
[5]  
Mathers C(2013)The management of the advanced colorectal cancer: management of the pulmonary metastases J Thorac Dis 5 8-154
[6]  
Rebelo M(2004)Staged pulmonary and hepatic metastasectomy in colorectal cancer—is it worth it? Eur J Cardiothorac Surg 25 151-1.e34
[7]  
Arnold M(2014)EURECCA colorectal: multidisciplinary management: european consensus conference colon & rectum Eur J Cancer 50 1.e1-1422
[8]  
Sierra MS(2016)ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 27 1386-1239
[9]  
Laversanne M(2012)The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus Oncologist 17 1225-1719
[10]  
Soerjomataram I(2016)Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database Lancet Oncol 17 1709-873